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Abstract
The endocannabinoid system plays a central role in retrograde synaptic communication and may control the spread of
activity in an epileptic network. Using the pilocarpine model of temporal lobe epilepsy we examined the expression pattern
of the Type 1 cannabinoid receptor (CB1-R) in the hippocampi of CD1 mice at survival times of 2 hours, 1 day, 3 days and 2
months (acute, latent and chronic phases). Based on the behavioral signs of the acute seizures, animals were classified as
‘‘weakly’’ or ‘‘strongly’’ epileptic using the modified Racine scale. Mice of the weak group had mild seizures, whereas
seizures in the strong group were frequent with intense motor symptoms and the majority of these animals developed
sclerosis in the chronic phase. In control samples the most intense staining of CB1-R-positive fibers was found in the
molecular layer of the dentate gyrus and in str. pyramidale of the cornu Ammonis. In weak animals no significant changes
were seen at any survival time compared to controls. In strong animals, however, in the acute phase, a massive reduction in
CB1-R-stained terminals occurred in the hippocampus. In the latent phase CB1-R immunoreactivity gradually recovered. In
the chronic phase, CB1-immunostaining in sclerotic samples was stronger throughout the hippocampus. Quantitative
electron microscopic analysis showed an increase in the number of CB1-R-positive terminals in the dentate gyrus. Moreover,
the number of immunogold particles significantly increased in GABAergic terminals. Our results suggest a proconvulsive
downregulation of CB1 receptors in the acute phase most probably due to receptor internalization, followed by
compensatory upregulation and sprouting in the chronic phase of epilepsy. In conclusion, the changes in CB1 receptor
expression pattern revealed in this study are associated with the severity of hippocampal injury initiated by acute seizures
that ultimately leads to sclerosis in the vulnerable regions in the chronic phase.
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Introduction
Epilepsy is one of the most common neurological diseases
affecting 1–3% of the population [1,2]. At the neuronal network
level it manifests as states of pathological hyperexcitability and
hypersynchronous activity. Imbalanced synaptic input may cause
excessive neuronal activity, eventually leading to neuronal death and
synaptic reorganization [3,4,5]. Understanding the underlying
mechanismsiscrucial forthe development ofneweffective therapies.
The endocannabinoid system is involved in numerous physio-
logical functions like food intake, pain sensation and memory
formation. In the brain, the endocannabinoid system is responsible
for retrograde synaptic signaling via CB1-R (Type 1 cannabinoid
receptor) [6,7,8]. Endocannabinoids are released from the
postsynaptic neurons in an activity-dependent manner, and bind
to presynaptic CB1-Rs, thereby suppressing transmitter release
from presynaptic terminals [9,10,11,12,13,14,15,16,17].
In addition to its physiological roles, this system was found to be
affected in pathological processes as well. Controversial data were
published regarding the effects of cannabinoids in epilepsy. On
one hand, in an animal model of TLE (temporal lobe epilepsy),
CB1-R agonists displayed anti-epileptic effects [18], in addition,
CB1-Rs on glutamatergic axon terminals were shown to mediate
anticonvulsant effect, by attenuating glutamate release [19,20]. On
the other hand, proconvulsive effects of CB1-R agonists were
described as well [21,22,23]. Moreover, a CB1-R antagonist was
shown to prevent the long-term increase in seizure susceptibility
when applied in a certain time-window [24,25].
Human studies showed that recurrent seizures may lead to an
adverse reorganization of the endocannabinoid system and to the
impairment of its protective effect [26,27]. CB1-Rs located at
inhibitory synapses can be upregulated in the dentate gyrus [28],
whereas downregulation of CB1-Rs located at excitatory synapses
may occur in the inner molecular layer of the dentate stratum
moleculare [27]. In the pilocarpine model of epilepsy downreg-
ulation of CB1-Rs located at inhibitory synapses was found in the
acute phase [29,30], but upregulation occurred in the chronic
phase [18].
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both at excitatory and inhibitory synapses in different phases of
epileptogenesis has not been carried out in this model of epilepsy
so far.
Using the pilocarpine model of temporal lobe epilepsy we
examined the expression pattern of CB1-Rs on both glutamatergic
and GABAergic axon terminals at light and electron microscopic
levels in the hippocampi of CD1 mice. In the acute phase of
epilepsy a considerable downregulation of the receptor was found.
Effects of the loss of receptors were examined in mice lacking CB1-
Rs. In the knock out animals we show that seizures are more
severe in most animals, moreover, survival rates worsen during
acute seizures compared to wild types. However, in wild type
animals in the chronic phase an upregulation of CB1-Rs occurred
throughout the hippocampus which may serve as a neuroprotec-
tive mechanism (via decreasing excitability and synchronization by
reducing glutamate and GABA release). Nevertheless, during the
acute seizures the high concentration of the ligand may be
responsible for transient internalization/downregulation of the
receptor [23,31,32] and increasing seizure susceptibility.
Materials and Methods
The model
Animals were kept under standard conditions with 12 h dark-
light cycle; food and water were supplied ad libitum. Experiments
were performed according to the guidelines of the Institutional
Ethical Codex & the Hungarian Act of Animal Care &
Experimentation (1998, XXVIII, Section 243/1998), The Animal
Care and Experimentation Committee of the Institute of
Experimental Medicine of Hungarian Academy of Sciences and
the Animal Health and Food Control Station, Budapest, has
approved the experimental design under the number of 2303/
003/FO ˝ V/2006. The experiments are in accordance with 86/
609/EEC/2 Directives of European Community, which is in full
agreement with the regulation of animal experiments in the
European Union. All efforts were made to reduce the number of
animals used and to minimize pain and suffering. For this animal
model 20–30 g male CD1 mice (Harlan, Italy) and CB1-R knock-
out CD1 mice were used [33]. Animals were assigned to control
and experimental groups. Age-matched control mice were injected
with physiological saline (12 animals, 0.1 ml/30 g) or scopolamine
(12 animals 5 mg/kg). Since no difference was found between the
two control groups, during the following experiments, control mice
were injected with physiological saline. Experimental mice were
injected with intraperitoneal Pilocarpine hydrochloride (340 mg/
kg, Sigma) to induce status epilepticus (SE). Scopolamine methyl
nitrate (5 mg/kg, Sigma) was injected 30 minutes in advance to
prevent peripheral cholinergic effects of pilocarpine. No benzodi-
azepine treatment was used to stop seizures. By omitting
antiepileptic drugs we were able to examine seizure-induced
changes 2 hours post SE, without further alteration of the
GABAergic function by additional drugs.
Animals were observed for two hours after the pilocarpine
injection, and the behavioral signs of seizures were monitored and
scored. At every 5 minutes or when behavioral changes occurred a
score was determined. Acute seizures started 5–15 minutes after the
pilocarpine administration (post pilo). Seizures were classified by
using the modified Racine’s scale [34] (1–5), animals wereseparated
into ‘‘weak’’ and ‘‘strong’’ groups according to their seizure activity
[28]. Seizure activity was defined for every animal by using the
maximal value of Racine -scale reached more than once.
In the weak group mice developed only a few mild seizures
characterized by few ictal seizure period in the EEG accompanied
with startling and shaking, whereas in the strong group the seizures
were frequent and EEG showed several ictal seizure periods
behaviorally represented by intense motor symptoms including
jaw movements, salivation, and forelimb clonus with rearing and
tonic-clonic seizures [28,34,35].
Acute phase was examined 2 hours after pilocarpine injection.
The period examined 1–3 days after the injection was regarded as
the latent phase. At day three mass cell loss began, therefore this
time point was considered as the end of the latent phase. EEG
recordings were carried out 1 month after pilocarpine treatment in
the chronic phase, at this time point recurrent seizures occurred in
most of the strong epileptic animals.
We examined the expression pattern of CB1-Rs in the
hippocampus at different survival times: 2 hours after the
treatment in the acute phase, 1 and 3 days after the treatment
in the latent phase and 1–2 months after the treatment in the
chronic phase.
In vivo electrophysiology
We proved the occurrence of recurrent electrographic seizures
with EEG recordings in the chronic phase. Mice were anesthetized
with a 1–1.5% halothane-air mixture (Narcotan, Leciva, Praha,
Czech Republic) and secured in a stereotaxic frame (David Kopf,
900 USA, equipped with a SUPERTECH Ltd. made mouse
adaptor HU).
Five holes were drilled into the skull above the frontal and
parietal lobe bilaterally and above the cerebellum (reference).
Stainless steel wire electrodes (MEDWIRE SST1) were placed on
the skull and covered with conductive paste (Ten20, USA) to
decrease the impedance. The electrodes and the connector were
embedded in dental acrylic cement (GS, Japan). This way the
electrodes were firmly implanted to the skull but the dura was not
pierced. The EEG activity was recorded by a Grass EEG 8B
model (Grass Instruments, Quincy, MA, USA), filtered at 1 Hz to
70 Hz and amplified (20 k). Data were recorded with a CED 1401
system using SPIKE2 v2.1 software (Cambridge Electronic Design
Limited, Cambridge, UK). Sampling rate was 500 Hz, amplifica-
tion 20 mV/mm, filter: LP: 70 Hz, HP: 1 Hz.
Recordings were made for 3 days, in the morning (9 AM) and
in the afternoon (4PM) for 1.5 hours. The behaviour of the
animal was observed during EEG recording. To answer the
question whether animals had different diurnal and noctur-
nal epileptic activity, 24-hour continuous EEG monitoring was
also carried out in 4 animals (2 controls, 2 chronically epileptic
mice).
Analysis of the EEG recordings
All EEG recordings were evaluated by three independent and
experienced researchers to determine the occurrence of seizures or
interictal spikes [36]. EEG recordings were carried out in 16 mice
(6 controls, 4 weak and 6 strong epileptic) in the chronic phase. In
4 animals (2 controls, 2 chronically epileptic ones) 24-hours EEG
monitoring was carried out.
Epileptic activity was considered as interictal burst when the
amplitude of occasionally appearing EEG spike activity was three
times higher than the normal resting control EEG waves. The ictal
EEG was determined so that the appearance of large amplitude
EEG spikes was continuous and that activity pattern lasted for at
least 5 seconds. Occasionally, an increase of frequency and
decrease of amplitude of large spikes were seen prior to the ictal
event. That phase was considered as interictal activity. Data were
analyzed with SPIKE2 v2.1 software (Cambridge Electronic
Design Limited, Cambridge, UK).
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Two hours after pilocarpine injection, control and ‘‘strong’’
epileptic mice (two of each) were deeply anesthetized with
isoflurane (Abbott Labs, USA) After decapitation, the brain was
quickly removed and placed into ice-cold artificial CSF containing
(in mM): sucrose, 252; KCl, 2.5; NaHCO3, 26; CaCl2, 0.5; MgCl2,
5; NaH2PO4, 1.25; glucose, 10, and bubbled with 95% O2 and
5% CO2 (carbogen gas). We prepared 400- mm-thick coronal slices
using a Leica (Nussloch, Germany) VT1000S microtome. Slices
containing the hippocampal formation were trimmed from other
brain regions. 2 slices of each animal were immediately transferred
to fixative containing 0.05% glutaraldehyde (TAAB, UK), 4%
paraformaldehyde (TAAB, UK) and 15% picric acid in 0.2 M
phosphate buffer (PB), whereas other slices were kept in an
interface-type holding chamber at room temperature for 2 hours,
before fixation. After overnight fixation, CB1-immunostaining was
carried out.
Tissue preparation
Animals were sacrificed at different survival times including
2 hours (n=22), 1 day, 3 days (n=48), 1 month and 2 months
(n=105) after pilocarpine administration. Mice were perfused
under equithesine anesthesia (chlornembutal 0.3 mL/100 g), first
with physiological saline (1 min) and then with a fixative
containing 0.05% glutaraldehyde (TAAB, UK), 4% paraformal-
dehyde (TAAB, UK) and 15% picric acid in 0.1 M phosphate
buffer (PB) for 30 min.
Immunocytochemistry
Brains were removed from the skull and 60 mm thick vibrotome
sections were cut from the blocks. Following washing in PB
(6610 minutes), sections were cryoprotected in 30% sucrose for 1–
2 days, followed by freezing three times over liquid nitrogen.
Sections were processed for immunostaining against CB1-R (from
Prof. M. Watanabe, Hokkaido University, Sapporo, Japan)
(described by Fukudome et al., 2004 [37]), Neuronal Specific
Nuclear Protein (NeuN) and Heat Shock protein 72 (HSP72) as
follows. Sections were transferred to Tris-buffered saline (TBS,
pH 7.4), then endogenous peroxidase was blocked by 1% H2O2 in
TBS for 10 min. TBS was used for all the washes (3610 min
between each step) and dilution of the antisera. Non-specific
immunostaining was blocked by 5% normal goat serum, 0.1 g/ml
glycine, 0.1 g/ml lysine. A polyclonal guinea pig antibody against
CB1-R (1:1000), monoclonal mouse antibody against NeuN
(1:4000 Chemicon) and a monoclonal mouse antibody against
HSP72 (1:800, Calbiochem) were used for 2 days at 4uC. The
specificity of the antibody has been thoroughly tested by the
manufacturer and in our laboratory using CB1 knock out mice
[38]. For visualization of immunopositive elements, biotinylated
anti-guinea pig or anti-mouse immunoglobulin G (IgG) (1:250,
Vector, 2 hours) was applied as secondary antiserum followed by
avidin-biotinylated horseradish peroxidase complex (ABC; 1:250,
Vector, 1.5 hours). The immunoperoxidase reaction was devel-
oped by 3,39-diaminobenzidine tetrahydrochloride (DAB; Sigma)
as a chromogen dissolved in TRIS buffer (TB, pH 7.6). Sections
were then treated with 1% OsO4 in PB (40 min) and dehydrated
in ethanol (1% uranyl acetate was added at the 70% ethanol stage
for 40 min) and mounted in Durcupan (ACM, Fluka). The control
sections were processed in the same way. For immunogold staining
against CB1-R, the sections were blocked by 5% normal goat
serum, 0.1 g/ml glycine and 0.1 g/ml lysine (GE Healthcare UK
Limited). Incubation in anti-CB1 guinea pig antiserum (1:1000, 2
days) was followed by a second blocking step with 5% normal goat
serum, 0.1 g/ml glycine, 1 g/ml lysine and 0.1% fish gelatin.
Secondary antiserum was ultra small gold conjugated goat anti-
guinea pig (1:50, overnight incubation, Aurion). Gold labeling was
intensified using the R-Gent silver intensification kit (Aurion,
Wageningen, The Netherlands). Sections were then osmicated
(0.5% OsO4, 30 min, 4uC), dehydrated and embedded in
Durcupan. The control hippocampi were processed in the same
way.
After light microscopic examination, areas of interest were re-
embedded and sectioned for electron microscopy. Ultrathin serial
sections were collected on Formvar-coated single slot grids, stained
with lead citrate, and examined with a Hitachi 7100 electron
microscope.
Gallyas silver impregnation
Degenerated neuronal elements were visualized with the
staining procedure of Gallyas et al. [39]. The steps of this staining
are the following: 265 min in the pretreating solution (2% NaOH
and 2.5% NH4OH), 10 min in the impregnating solution (0–0.8%
NaOH, 2.5% NH4OH, 0.5% AgNO3), 365 min in washing
solution (0.5% Na2CO3 and 0.01% NH4NO3 in 30% ethanol),
1 min in developing solution (0.4–0.6% formaldehyde and 0.01%
citric acid in 10% ethanol, pH 5.0–5.5), 3610 min wash in 0.5%
acetic acid. Afterwards sections were mounted on gelatin-coated
slides, dehydrated in xylene and covered with XAM neutral
medium (BDH, Poole, UK).
Determination of principal cell loss
In the chronic phase, the severity of the acute seizures (using the
Racine-scale, seizures from 1 to 5) was correlated with the cell-loss
found in CA1, CA3 and hilus. Cell loss was determined in case of a
large number of animals using a well defined semiquantitative
scale by two independent examiners as shown previously
[40,41,42]. Each region was classified as type 1–3 according to
the severity of cell death (type1: cell-loss under 10%, type2: cell-
loss between 10% and 50%, type3: cell-loss above 50%). Pearson
correlation was used to calculate the relationship between cell-loss
and seizure strength. Seizure strength was defined for every animal
by using the highest number of Racine scale reached during acute
seizures. This number, representative for each animal was
correlated with the severity of cell death (types 1–3) in each
subregion.
Quantitative electron microscopic analysis
Electron microscopic analysis was carried out in the dentate
gyrus, since this area is affected by seizure induced changes,
however granule cells are well-preserved even in case of robust
sclerosis in the CA1 [43,44] therefore it is possible to examine the
surviving elements which may not be the case in CA1. The
quantity of symmetric and asymmetric synapses established by
CB1-R-positive axon terminals was examined in the str.
moleculare of 3 control, 3 chronic epileptic and 3 acute epileptic
hippocampi. Serial sections were made from the blocks reem-
bedded from stratum moleculare and examined in the electron
microscope. CB1-R stained terminals were analysed in every 10th
section in order, following the rules of systematic random
sampling, to avoid sampling of the same axon terminals.
Photographs were taken of all terminals in a given area, and the
ratio of immunostained symmetric versus asymmetric synapses was
determined. To quantify the exact changes in the number of
stained terminals in the chronic and acute phase, we further
examined the str. moleculare. The number of CB1-R immuno-
stained terminals forming symmetric and asymmetric synapses was
calculated, both in control and in epileptic samples and
normalized. The studied areas were measured with NIH ImageJ
CB1 Receptors in an Animal Model of Epilepsy
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were normalized to unit area (40 000 mm
2).
To assess any changes occurring in the density of CB1-Rs per
terminals, the number of gold particles located in the membrane of
axon terminals was counted and normalized to a unit length of the
terminal’s perimeter (perimeter length was measured with NIH
ImageJ, number of particles was normalized to 1 mm). Significance
was tested using Mann-Whitney U-test (Statistica 6.0).
Results
The pattern of cell loss in pilocarpine induced epilepsy
As a first step, we carried out detailed investigations to clarify
the alterations of the hippocampal circuits on the pilocarpine
model of epilepsy using CD1 mice. Based on the behavioral signs
during the acute seizures, animals were classified as ‘‘weak’’ or
‘‘strong’’ epileptic using the modified Racine scale [28,34,35].
Animals showing seizure intensity from Racine 1 to Racine 4
(shaking, chewing, nodding, forelimb clonus, rearing but no tonic-
clonic seizures) were assigned to the weak group. However, in the
strong group all animals showed strong tonic-clonic seizures
(Racine 5) with other less severe seizure manifestations (Fig. 1).
We examined the cell loss pattern in the hippocampi at different
survival times using NeuN-immunostaining (Fig. 2)
In the acute phase (2 hours after the treatment) cell loss was
observed neither in the weak nor in the strong animals (data not
shown).
In the latent phase (1–3 days post-pilocarpine) loss of sensitive
interneurons (calretinin positive) and few principal cells could
already be seen in the CA1 and CA3 regions (3 days) (not shown).
Three days post pilocarpine, cell loss was usually patchy in the
CA1-3; occasionally pyramidal cells disappeared in larger areas.
In the chronic phase patchy cell loss was found infrequently in
‘‘weak’’ animals, but none of their hippocampi showed sclerosis
(Fig. 2B). In contrast, hippocampi of the ‘‘strong’’ mice showed
sclerosis in most cases (70%) meaning that CA1 and CA3 regions
were shrunken, atrophic and more than the half of the cells were
missing from the CA1 region. Loss of vulnerable interneurons was
also observed in all regions (Fig. 1)( Fig. 2C).
Based on the severity of cell death, the degree of damage of
subregions (CA1, CA3, dentate gyrus) was classified as type 1 (mild
cell loss), type 2 (patchy cell loss) and type 3 (sclerotic), defined
according to the following semiquantitative scale: type 1, up to
10% of the cells are damaged; type 2, 11–50% of the cells are
missing; type 3: more than 50% of the cells are missing. CA1 and
CA3 were considered sclerotic when cell loss exceeded 50%,
especially when strata oriens, pyramidale and radiatum could not
be separated any more [40,41].
Statistical analysis revealed a significant correlation (Pearson
correlation) between the degree of cell-loss and seizure strength in
Racine scale values (p,0.05) (105 animals) (Fig. 1). Thus,
behavioral signs of the acute seizures could be used to predict
the degree of cell loss in the chronic phase.
In vivo electrophysiological recordings
To prove the appearance of epileptic activity and recurrent
seizures, EEG recordings were carried out in 16 mice (6 controls, 4
weakly and 6 strongly epileptic) in the chronic phase. On the basis
of these recordings, the EEG activity of pilocarpine treated mice
differed from controls (Fig. 2D). Strong synchronization and
Figure 1. Table A describes seizure behavioral scoring for each Racine scale value. Graphs B, C and D show the correlation between
seizure intensity (Racine scale value) and cell loss (color code indicates cell loss from 0 to 3, where 0 refers to no cell loss, 1: cell-loss under 10%, 2: cell-
loss between 10% and 50%, 3: cell-loss above 50%) in CA1, CA3 and the hilus respectively. Correlation between Racine scale value and cell loss in the
regions proved to be significant using Pearson correlation (p,0.05).
doi:10.1371/journal.pone.0027196.g001
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members of the weak group (Fig. 2E) recurrent seizures were
rarely seen (in 1 mouse out of 4), while interictal spikes (incidence
2.262.26 Hz, amplitude 5816160 mV) occurred in all cases.
However, in members of the strong group recurrent seizures
appeared (ictal spikes with a frequency of 5.962.3 Hz, amplitude
5466112 mV) in nearly every animal (5 out of 6) (Fig. 2F). Thus,
the occurrence of recurrent seizures in the chronic phase showed
strong association with the severity of acute seizures.
One month after pilocarpine injection in 4 animals (2 controls, 2
strong) 24 hours long EEG monitoring was carried out to
investigate nocturnal epileptic activity. We observed seizure
activity in the EEG represented by spikes in all animals. No
animals showed exclusively nocturnal seizures, but they performed
recurrent seizures during the whole day. Seizure incidence was the
highest in the afternoon compared to other periods of the day.
HSP72 expression in the latent phase of epilepsy (1, 3
days post pilo)
To examine whether anatomical differences occur at an early
time point between animals with strong or weak seizures,
immunostaining against Heat Shock Protein 72 (HSP72) was
carried out to visualize cells suffering from excitotoxic damage,
since this protein confirms the emergence of abnormal proteins
due to various damaging effects [41,45,46].
In control hippocampi (Fig. 3A) immunostained cells were
never seen, light background staining appeared occasionally in the
layers of principal cells.
In the acute phase of epilepsy (2 hours after injection) no
significant alteration was observed with HSP72 immunostaining,
the hippocampi of both weak and strong animals were control-like
(data not shown).
In the latent phase positive cells were not seen in weak epileptic
animals (Fig. 3B), however, in members of the strong group
robust changes occurred 1 day after the induction of the seizures
(Fig. 3C). Principal cells with Golgi-like HSP-staining appeared in
the str. pyramidale of the CA3, and among the granule cells in the
dentate gyrus. Occasionally immunopositive cells were seen in the
CA1 str. pyramidale as well.
Three days after pilocarpine treatment weak samples displayed
the same appearance seen in controls (not shown), with a modest
increase in background staining. In contrast, in the hippocampi of
strongly epileptic animals a marked increase in HSP72 expression
was found in CA1 (Fig. 4 A, B) and CA3 (mostly CA3c)
pyramidal cells, and in the mossy cells of the hilus (Fig. 4 C).
However, three days post pilocarpine fewer granule cells were
stained compared to samples 1 day after pilocarpine.
These results prove that cellular differences can be seen between
animals with different acute behaviour; validating our classifica-
tion into ‘‘weak’’ and ‘‘strong’’ groups. Irreversibly damaged cells
were visualized with Gallyas silver impregnation (Fig. 4D–F). One
day after pilocarpine injection dark silver deposit was present in
hilar neurons undergoing agyrophilic degeneration (not shown).
Three days after pilocarpine silver accumulation appeared in
additional subregions; besides strata pyramidale and radiatum of
the CA1 (Fig. 4E) degenerating somata and dendrites appeared in
the hilus (Fig. 4F).
Analysis of CB1-R distribution in different phases of
pilocarpine-induced epilepsy
Distribution of CB1 receptors in control tissue. In
control samples intense CB1-R immunostaining was found
throughout the hippocampus. Immunopositive cell bodies of
interneurons were seen in all hippocampal subfields, mostly in
strata radiatum and lacunosum-moleculare of CA1 and CA3, as
well as at the border of the hilus and in the inner molecular layer
of the dentate gyrus. Intense staining of CB1-R-positive fibers was
found in stratum pyramidale of the cornu Ammonis (Fig. 5A) and
in the molecular layer of the dentate gyrus (DG) (Fig. 5C). In
contrast, less dense labeling was observed in the strata radiatum
(Fig. 5A) and granulosum (Fig. 5C) [38,47,48].
At the electron microscopic level numerous immunopositive
axon terminals were found forming symmetric or asymmetric
synapses. Immunogold particles indicating the presence of CB1-Rs
was located predominantly perisynaptically as described earlier
([49,50]. Glial cells and processes were not immunopositive either
in control or in epileptic tissue.
Distribution of CB1 receptors in the acute phase of
epilepsy (2 hours). In the acute phase, epileptic hippocampi
from members of the weak group showed control-like phenotype:
no major changes were seen in the distribution and density of
immunolabelled elements. In contrast, in the strong group a robust
Figure 2. Anatomical and physiological changes in pilocarpine induced epilepsy. Light micrographs of control (A) and epileptic (B, C)
animals immunostained for NeuN. Animals survived for 1 month after pilocarpine treatment. Compared to control mice (A), in non-sclerotic ‘‘weak’’
animals (B) only mild, restricted changes (arrow) are seen occasionally in the hippocampus. In the sclerotic hippocampi of ‘‘strong’’ animals (C) a
characteristic pattern of neuronal damage appears. The principal cell loss is over 50% (sclerosis) mostly in CA1 and CA3 (arrows) and in the hilus. In
the EEG recordings of control animals no ictal or interictal acitivity can be seen (D), however, in weak animals (E) interictal spikes (arrowheads) occur
frequently. In strong animals (F) recurrent seizures are observed in most cases, both interictal and ictal (arrows) activity appeares. An increase in
frequency and decline in amplitude can be seen immediately preceding and after the seizures. Scale (A, B, C): 200 mm.
doi:10.1371/journal.pone.0027196.g002
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hippocampus, namely, the dense axonal meshwork seen in the
strata moleculare, radiatum and oriens of controls was sub-
stantially reduced (Fig. 5B, D). Moreover, CB1-R immunoposi-
tive boutons forming baskets in the principal cell layers could
hardly be seen at light microscopic level (Fig. 5B).
Reversible changes in CB1-R expression in acute slices
(2 hours post pilo). To investigate the electrophysiological
correlates of our anatomical findings observed in acute phase, we
planned to record the effects of CB1–R activation on hippocampal
function. In vitro slices were prepared from the hippocampi of
control and strongly epileptic animals. As a first step, immu-
nostaining for CB1-Rs was carried out on the slices at two time
points: immediately fixed after the slice cut and after 2 hours of
incubation in an interface-type holding chamber. Surprisingly, we
observed that after 2 hours of incubation, slices from strongly
epileptic animals showed control-like distribution of CB1-Rs
(Fig. 6A, C, and D). However, when slices from the same
animals were immediately fixed after cutting, a similar decrease in
CB1-R distribution was found as seen in perfusion fixed animals
compared to controls (Fig. 6B).
These data suggest that under our circumstances the conse-
quences of the acute phase on hippocampal CB1-R function
cannot be studied using in vitro slice preparations, since the
changes in CB1-R distributions after acute seizures recovers within
the incubation time that has to precede recording.
Since functional consequences of CB1-R decrease could not be
established with in vitro methods, we studied the seizures of animals
a priori, lacking CB1-Rs.
Increasedmortality afterseizuresinCB1 KOanimals. We
addressed the question how seizure susceptibility changes in CB1-R
knock out mice, therefore 22 controls were examined, 22 CB1-R
knock out animals and 21 wild type littermates were injected with
pilocarpine in a different set of experiments. CB1-R KO animals
received very intense seizures (typical for strong epileptic animals)
they were more susceptible to epilepsy as only 3 animals had mild
seizures out of 22 and all 19 animals showing strong seizures died in
15 minutes (Fig. 7). Mice receiving only mild or no seizures
(members of the weak group), survived and were sacrificed in the
chronic phase. These animals showed no signs of anatomical
alterations, NeuN and Gallyas labeling was similar to the staining
in weak wild type littermates (not shown).These results may suggest a
protective role of CB1-R activation in epilepsy as it has been shown
previously [20,51,52].
Ultrastructural changes of CB1-R expression in the acute
phase of epilepsy. At the electron microscopic level
occasionally degenerating profiles were observed throughout the
hippocampus. They were mostly oedemic dendritic profiles, axon
terminals and spines; however, they were not selectively CB1-R-
positive. To quantify the changes, systematic random sampling
was carried out. We could not take advantage of dissector method,
since one cannot obtain accurate counts in a reasonable time when
structures of interest form a very small fraction [53]. Moreover, we
wished to minimize alterations caused by the sprouting of non-
positive fibers in the examined area, therefore, we have examined
a large area (.40.000 mm2) in a single plane.
To confirm changes caused by swelling we measured the
perimeter of immunopositive terminals. A total of 298 terminals
were digitized (169 of control tissue, 129 of strong epileptic tissue)
and analyzed. Compared to controls a significant increase in
perimeter (p,0.05; Mann-Whitney test) was found in case of
terminals forming symmetric synapses (control: 260.67 mm,
strong epileptic: 2.6360.87 mm) however, no such difference was
observed among stained terminals forming asymmetric synapses
(control: 1.960.76 mm, strong epileptic: 2.1260.9 mm). After-
wards we compared the ratio of immunolabelled axon terminals
establishing symmetric versus asymmetric synapses in the same
sample of 298 terminals (Fig. 8A). The percentages of CB1–R
immunopositive axon endings forming symmetric and asymmetric
synapses found in acute epileptic samples (Fig. 8E,H) were
calculated and compared to the percentage observed in controls
(Fig. 8D,G). The analysis revealed no significant change in these
ratios (control: 79.667.6% in case of asymmetric and 20.467.6%
in case of symmetric synapses; strong epileptic: 8064% in case of
asymmetric and 2064% in case of symmetric synapses, p.0.05;
Mann-Whitney test) (Fig. 8A). To uncover changes in the overall
number of stained terminals, we counted every stained terminal in
Figure 3. Demonstration of excitotoxic insult 1 day after
pilocarpine treatment. In animals of the ‘‘weak’’ group (B) HSP72-
immunostaining is control-like (A), only a slight increase in background-
staining can be seen, but no stained cells with processes appear.
Although there are no morphological signs of neuronal degeneration at
this early stage in the hippocampi of ‘‘strong’’ epileptic animals (C)
either, the vulnerable cells as well as the resistant granule cells start to
express HSP72, and are stained in a Golgi-like manner. Faint
homogeneous staining of CA1 pyramidal cells can also be seen. Scale:
200 mm.
doi:10.1371/journal.pone.0027196.g003
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area (40 000 mm
2). Compared to control tissue, a significant
decrease was found in the number of labeled asymmetric and
symmetric synapses (control asymmetric: 18.962.3; symmetric:
660.2; strong epileptic asymmetric: 11.863.7, symmetric:
3.260.7; p,0.05; Mann-Whitney test) (Fig. 8B). Taken together,
the results imply that mechanism(s) other than axon terminal
degeneration could account for the loss of CB1-R staining in the
acute phase of epilepsy.
To understand further changes in CB1-R expression we
examined other phases as well.
Distribution of CB1 receptors in the latent phase of
epilepsy (1 and 3 days post pilo). One day after pilocarpine
injection CB1-R levels were control-like both in weak and strong
animals. Three days after pilocarpine injection upregulation of
CB1-R immunoreactivity occurred in some animals of the strong
group. There was a gradual recovery in CB1-R intensity 1 and 3
days post pilo. 3 days after SE principal cells began to degenerate
(Fig. 4) and HSP72 staining was more extended referring to
excitotoxic damage caused by the initial seizures. However, in the
latent phase the decreased intensity of the receptor staining was
not observed any longer. CB1-R staining proved to be control-like
or moderately increased.
Distribution of CB1 receptors in the chronic phase of
epilepsy (1 and 2 months). To study the long-term changes in
CB1-R levels, their distribution was examined one month after
pilocarpine injection, in the chronic phase. In general, similar
alterations in CB1-R staining were found in these animals as we
observed earlier with antibody recognizing only CB1-R at
inhibitory terminals (Magloczky et al., 2010) (Fig. 9A, C). In
epileptic animals of the weak group the distribution of CB1-Rs was
mostly control-like. Occasionally, a highly restricted upregulation
appeared in str. pyramidale of CA1. In the sclerotic samples the
general CB1-R immunostaining was enhanced throughout the
hippocampus. The density of immunostained fibers in CA1
increased heavily in surviving elements of strata pyramidale and
radiatum (Fig. 9B). Similarly, in DG a dense CB1-R-positive
axonal plexus was found in strata moleculare and granulosum
(Fig. 9D). Immunopositive interneuron somata were present both
in the dentate gyrus and in the CA1 and CA3 areas.
Ultrastructural analysis of CB1-R distribution in the
chronic phase. At the electron microscopic level, numerous
glial elements and occasionally degenerating profiles were seen,
changes that are typical for epileptic tissues [2], however glial
elements were not positive for CB1-R staining. The general
ultrastructural features of CB1-R-positive elements were
Figure 4. Cell loss and degeneration at day 3 post pilocarpine. HSP72 is heavily expressed in a large population of pyramidal cells (A, B) and
in some mossy cells, indicating that they were exposed to excitotoxic insult. In contrast, hardly any granule cells are stained (arrows) (C) compared to
1 day post SE. Gallyas silver impregnation reveals that in the early latent period principal cell loss begins at a large scale (orange cells are alive). Dark
silver deposit is present in neurons irreversibly damaged (D, E, F). Argyrophilic cell degeneration can be seen in the vulnerable regions of the
hippocampus, like the CA1 pyramidal cell layer (E) and the hilar region (F) (arrows in the CA1, arrowheads in the hilus). (s.o.: str. oriens, s.p. str.
pyramidale, s.r.: str. radiatum, s.m.: str. moleculare, s.g.: str. granulosum) Scale: A, D 200 mm, B, E, F, C and F: 50 mm.
doi:10.1371/journal.pone.0027196.g004
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significantly (p,0.05) (Fig. 8A, B). Changes in the ratio of stained
terminals establishing symmetric versus asymmetric synapses were
analyzed (169 controls, 178 strong epileptic). In epileptic animals
the ratio was significantly changed; the mean percentage in control
tissue was 79.667.64% in case of asymmetric (Fig. 8G)a n d
20.467.6% in case of symmetric synapses (Fig. 8D), in strong
epileptic tissue 51.463.9% of the examined terminals proved to be
asymmetric (Fig. 8I) whereas 48.663.9% was symmetric (Fig. 8 F)
(p,0.05; Mann-Whitney test) (Fig. 8A). These results may suggest
either a loss of stained asymmetric synapses or an increase of
symmetric synapses, or both.
To address this question, we used systematic random sampling
as described above and digitized every stained terminal in a given
area of str. moleculare, and normalized the results to unit area
(40.000 mm
2). Compared to control tissue a significant increase
was found in the number of CB1-R-positive asymmetric and
symmetric synapses (control asymmetric: 18.962.3 symmetric:
660.2; epileptic: asymmetric: 34.9610.9, symmetric: 32.3618.5,
p,0.05; Mann-Whitney test), (Fig. 8B). During the analysis of
immunogold-labeled axon terminals, in certain terminals we
noticed an increase in the number of immunogold particles in
the hippocampi of chronically epileptic animals of the strong
group (Fig. 8).
To quantify these changes, immunogold particles were counted
in 302 (125 controls and 177 strong epileptic) terminals. The
number of gold particles in the membrane of CB1-R stained axon
terminals forming symmetric or asymmetric synapses was counted
and normalized to unit perimeter of the axonterminal membrane
(particle/1 mm). No difference was found between asymmetric
synapses in control and epileptic tissue in the average quantity of
gold particles (control: 0.6460.27, strong epileptic: 0.63360.46,
p.0.05, Mann-Whitney test). In contrast, the number of
immunogold particles significantly increased in axon terminals
forming symmetric synapses (control: 0.6960.29, strong epileptic:
0.9960.49, p,0.05, Mann-Whitney test) (Fig. 8C,F). No similar
change was observed in tissue samples derived from strong animals
in the acute phase neither in asymmetric synapses (control:
0.6460.27, strong epileptic: 0.6360.33) nor in case of symmetric
synapses (control: 0.6960.29, strong epileptic: 0.5960.34
Figure 5. Changes of CB1-R-staining in the acute phase. In control samples intense staining of CB1-R-positive fibers can be seen in CA1
stratum pyramidale and radiatum (A) and in the molecular layer of the dentate gyrus (C). In the acute phase of epilepsy (2 hours after pilocarpine
injection) the hippocampi of strongly epileptic animals show decrease of CB1-R staining (B, D) compared to controls (A, C). The change is more
remarkable in CA1 than in the DG, where the faint diffuse staining of the inner str. moleculare is hardly affected. Scale: 50 mm.
doi:10.1371/journal.pone.0027196.g005
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establishing symmetric synapses significantly increased in strong
epileptic animals in the chronic phase (control: 1.9960.67 mm,
strong epileptic: 2.760.9 mm). No such change was observed in
terminals establishing asymmetric synapses (control: 1.8960.8 mm,
strong epileptic: 2.2260.93 mm).
In summary, we found that the number of immunolabelled
axon terminals forming asymmetric and symmetric synapses
increased in the chronic phase. In addition, the number of gold
particles indicating the presence of CB1-Rs was increased on
terminals forming symmetric synapses. These results may indicate
an elevation of CB1-R function in the chronic phase, which may
Figure 6. Reversible changes in CB1-R-staining in slice preparation (acute phase). In CA1 region of surviving brain slices 2 hours post
pilocarpine a massive decrease is seen in CB1-R staining in strongly epileptic animals (B) compared to scopolamine treated controls (A) as it was seen
in perfusion-fixed epileptic animals. In contrast, the slices from the same animals which were incubated in ACSF for an additional 2 hours the CB1-R
staining in the epileptic tissue (D) did not differ from control slices (C). Scale: 50 mm.
doi:10.1371/journal.pone.0027196.g006
Figure 7. Different behaviour and survival of knock out and wild type animals. Graph showing the number of animals as a function of
seizure strength demonstrates that knock out animals had more severe seizures compared to wild types and never survived tonic-clonic (Racine 5)
seizures.
doi:10.1371/journal.pone.0027196.g007
CB1 Receptors in an Animal Model of Epilepsy
PLoS ONE | www.plosone.org 9 November 2011 | Volume 6 | Issue 11 | e27196act as an extremely powerful circuit-breaker on GABAergic and
glutamatergic transmission (Katona&Freund, 2008).
Discussion
In our model various aspects of epileptic cell loss and
reorganization are similar to that seen in human TLE
[42,54,55,56,57,58]. On the basis of our results the strength of
seizures in the acute phase can be used to predict future changes
(e.g. cell loss) in the chronic phase. The vulnerability of cells
differed between ‘‘weak’’ and ‘‘strong’’ groups, as indicated by
HSP72-expression in the latent phase. The expression of CB1-Rs
related to the GABAergic and glutamatergic axon terminals was
strongly decreased without specific degeneration in the acute
phase, but in the chronic phase a significant upregulation
occurred in the number of immunostained terminals. In addition,
a significant increase was seen in the number of CB1-Rs in a
single terminal, but only in terminals forming symmetric
synapses.
Endocannabinoids as retrograde signal molecules are released
by large intracellular Ca
2+ transients, complex-spike burst-firing,
and/or phospholipase C activation via metabotropic receptors in
neurons [8,59]. They bind to presynaptic CB1 receptors located
on glutamatergic and GABAergic axon terminals, and thereby
Figure 8. Quantitative changes of CB1-Rs in the acute and chronic phase of epilepsy. Graph A shows changes in the ratio of CB1-R
immunopositive terminals establishing symmetric versus asymmetric synapses in control and epileptic tissue in str. moleculare of the DG. No
difference was found in the hippocampi of strong animals in the acute phase compared to controls. However, in strong animals in the chronic phase
a significant increase occurred in the ratio of stained symmetric versus asymmetric synapses. Graph B shows changes in the absolute number of
symmetric versus asymmetric synapses in control and epileptic tissue. Significant decrease was found in the number of stained asymmetric and
symmetric synapses in the hippocampi of strong animals in the acute phase, compared to controls. In contrast, in strong animals in the chronic
phase, the number of immunostained asymmetric and symmetric synapses significantly increased. Graph C shows changes in the normalized number
of gold particles in control and epileptic tissue. No difference appears in the mean quantity of gold particles in asymmetric synapses in control or in
epileptic tissue (acute or chronic phase). No difference was seen in case of symmetric synapses between the hippocampi of control and acute
epileptic mice either. However, in chronically epileptic tissue the number of gold particles located in symmetric terminals increased significantly.
Statistics were calculated with Mann-Whitney test (p,0.05). High power electron micrographs of CB1-R immunolabelled axon terminals from the str.
moleculare of the DG of controls (D,G) acute and chronic animals 2 hours (E, H) and 1month (F, I) post pilo. Our antibody labels both CB1-R-positive
terminals giving symmetric (D, E, F) and asymmetric (G, H, I) synapses. Gold particles are located extrasynaptically. In the chronic, strong tissue the
number of gold particles on terminals forming symmetric synapses has increased (F). Scale: 200 nm.
doi:10.1371/journal.pone.0027196.g008
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boutons arriving primarily onto the same neurons [13,14].
The question arises whether the different changes in the
endocannabinoid-mediated reduction of GABA and glutamate
release [60,61] contribute to seizure generation and maintenance,
or should it rather be considered as a neuroprotective reaction
[20,52].
Changes in the acute phase of epilepsy
Earlier investigations of short term changes in the endocanna-
binoid system revealed a robust downregulation in the acute phase
[29,30]. In these studies the loss of staining was explained by initial
cell death or the degeneration of terminals. In contrast, in our
samples mild degeneration was observed involving different
profiles which were rarely CB1-R-positive; moreover, swelling
was observed in case of immunostained terminals forming
symmetric synapses. In addition, in our study the acute phase
was examined 2 hours after pilocarpine injection. Previous studies
examined the ‘‘acute’’ phase at e.g. 9 hours to 1 week post SE
[30]. We were able to examine the acute changes as early as
2 hours post SE since we did not use benzodiazepines to terminate
seizures. This way we could demonstrate that acute changes of
CB1-R distribution are independent of cell loss and likely the
consequence of initial seizure activity.
Furthermore, the decrease of CB1-Rs in acute slices proved to
be a reversible change, since they were redistributed in the
membranes in a short time after ‘‘ending the seizures’’/sacrificing
the animals. Therefore, in vitro electrophysiology may not suitable
to examine functional changes in the acute phase. These
examinations suggest the occurrence of internalization and
recycling [62], or degradation shortly followed by de novo
synthesis.
Endocannabinoids are known to be synthesized in an acti-
vity-dependent manner [8,63,64]. In case of epileptic hyper-
excitation an increase may occur in endocannabinoid levels as
proposed previously and shown in kainic acid model of TLE
[19,23,31,65,66,67], thus CB1 receptors become strongly activat-
ed. Although CB1 receptor agonists are potent anticonvulsants
both in animal models and human patients with TLE [18,20,68],
their constant presence may cause internalization of the receptor
[69,70] or changes in conformation (forming homo-or heterodi-
mers) [71,72] leading to proconvulsive effects [21,22]. Therefore,
Figure 9. Changes in CB1-R-staining in the chronic phase. CB1-R immunostaining in the hippocampi of control (A, C) and chronically epileptic,
sclerotic mice (1 month post pilocarpine)(B, D). In the sclerotic samples the general CB1-R immunostaining is much stronger throughout the
hippocampus. In the CA1 (A) a dense immunostained axonal plexus can be seen in the sclerotic CA1 region (layers cannot be distinguished) (B). In the
dentate gyrus stained fibers establish more dense meshworks (D). Scales: A, C, D: 50 mmB :2 0mm.
doi:10.1371/journal.pone.0027196.g009
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by the timing of their application [25].
Changes in the chronic phase of epilepsy
In the chronic phase of epilepsy a massive increase of CB1-
staining located both at symmetric and asymmetric synapses was
found throughout the hippocampus. Our results differ from that of
Falenski et al [73] and Wyeth et al. [30], since in these studies the
loss of staining was sustained throughout the chronic phase as well,
at least in certain hippocampal subregions. This discrepancy could
be explained by differences between the models. In our study we
examined sclerotic animals with a cell loss pattern similar to that
seen in human TLE patients. In animal models described earlier
[30,73] different results were found depending on the model
conditions (e.g. termination of seizures by benzodiazepines or
severity of cell loss pattern).
Sprouting of excitatory fibers. Increased number of
glutamatergic terminals with CB1-Rs was found in the hip-
pocampi of sclerotic (strong epileptic) animals, most probably due
to the sprouting of mossy cell axons or CB1-R expressing sub-
cortical fibers. This highlights the importance of endocannabinoid
mechanisms in reducing glutamate release during epilepsy [19,20].
Recent findings show that the overexpression of CB1-Rs on
glutamatergic synapses can protect against excitotoxic damage
[52]. Moreover, increased effects of CB1-R agonists and elevated
levels of receptor protein were shown in the dentate gyrus of
pilocarpine treated mice [51].
Controversially, the innermost part of stratum moleculare was
examined previously by Ludanyi et al. showing that a downreg-
ulation of CB1-Rs related to glutamatergic terminals occurs in the
inner molecular layer of the dentate gyrus in human TLE patients
[27]. In the study of Ludanyi et al. the ratio of CB1-R stained
asymmetric synapses was calculated by comparing the number of
stained terminals to the number of unstained terminals in a given
area. However, intensive sprouting of excitatory axon terminals in
the stratum moleculare occurs in the epileptic tissue as it was
described earlier (Magloczky et al. 2000; [1,74,75]. The increased
amount of CB1-R unstained terminals may explain the decreased
ratio of CB1-R-positive boutons found by Ludanyi et. al. Another
reason for this discrepancy can be the different method for
quantification. In our study exclusively CB1-R-postive terminals
were quantified in a large area of str. moleculare.
In addition, a recent study showed that an increased CB1-R
availability could be observed in human TLE, which correlated
negatively with the latency following the last seizure [26], therefore
CB1-R expression seems to be regulated very dynamically, which
may easily explain differences between the results.
Sprouting of inhibitory fibers, changes in perisomatic
inhibition. In the chronic phase of epilepsy CB1-R-positive
(and also CCK-positive) cell bodies were preserved in the dentate
gyrus and in the CA1 area, despite the mass principal cell loss.
Enhancement of the immunostained terminal density deriving
from the surviving CB1-R-positive interneurons was associated
with the degree of cell loss [27,28].
In case of CB1-Rs located in terminals establishing symmetric
synapses a strong increase in CB1-R-immunostaining was found
both in the hippocampi of epileptic patients and in mice with CA1
sclerosis [28]. Moreover, we found an increase of CB1-R level on
single GABAergic terminals in parallel with an increase of
terminal perimeter. Results of Chen et al. [76] show a chronic
increase of CB1-Rs on axons of cholecystokinin-containing
inhibitory cells following febrile seizure-like events. Our previous
study, showing the sprouting of CB1-R-expressing interneuronal
fibers and the elevation of CB1-R levels both in a chronic model
(pilocarpine) and in human patients highlights the involvement of
the reorganized endocannabinoid system in the chronic phase of
temporal lobe epilepsy [28]. In addition, the increase in the size of
inhibitory terminals may have a role in sustaining a more effective
inhibition as proposed previously [77,78].
Sprouting of CB1 expressing neurons related to GABAergic
fibers (mostly CCK-containing cells [17] may have controversial
effects depending on the depolarizing or hyperpolarizing effect of
GABA. If GABA is hyperpolarizing, proconvulsant effects of CB1-
Rs could occur, by reducing GABAergic inhibition [24]. However,
in case of altered ion homeostasis, GABAA receptors may have
depolarizing effects [81,82,83,84,85,86,87], thus reduced GABA
release would be anticonvulsive.
GABA release causing hyperpolarization may be anticonvulsant
as well, since enhanced perisomatic inhibition in chronic epilepsy
was proposed to have a role in synchronizing seizure activity
[42,58,76,79,80]. In addition, in epileptic tissue the axons of
perisomatic targeting interneurons often sprout, suggesting an
enhancement in this type of inhibition [42,80].
Consequently, the effect of altered CB1-R distribution may
depend on the current network state and ion homeostasis.
Reduced transmitter release may decrease seizure intensity in
case of glutamate release, and also in case of GABA release, when
GABA has a hypersynchronizing or depolarizing effect. These
scenarios, if they occur during epileptic seizures, may lead to an
antiepileptic network effect of the increased density of CB1-Rs.
Conclusions
We showed that early seizures can determine the severity of
future epileptic events. With the neurochemical marker HSP72
different mechanisms were shown to activate in strong and weak
animals leading to profound differences also in the chronic
phase.
In case of CB1-R-staining, robust changes were only found in
animals with strong acute seizures. In animals with milder seizures
and hardly any cell loss, changes in CB1 distribution remained
undetectable with the current methods. However, it is important
to consider that in human TLE patents sclerosis is the most
common cell loss pattern; therefore, alterations in animals with
similar cell loss are likely to be relevant in human TLE.
The death of CB1 KO animals with strong acute seizures
suggest that CB1 receptors may have a key role in the control of
the first seizures, and thereby may prevent the seizures from
reaching the ‘‘no-return’’ state. Thus, the decrease of CB1-Rs in
animals with strong acute seizures may lead to elevation of
glutamate release during acute seizures, as well as to the
subsequent development of recurrent seizures, reorganization
and cell loss. The increased density of CB1-Rs in the chronic
phase may serve as a protective mechanism in most cases as
proposed in earlier studies, and confirmed in the present study as
well [26,52].
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